BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9673144)

  • 1. Principles of therapy for tuberculosis.
    Ortona L; Antinori A
    Rays; 1998; 23(1):181-92. PubMed ID: 9673144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuberculosis susceptibility patterns, predictors of multidrug resistance, and implications for initial therapeutic regimens at a New York City hospital.
    Weltman AC; Rose DN
    Arch Intern Med; 1994 Oct; 154(19):2161-7. PubMed ID: 7944836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
    Yoshiyama T; Ogata H; Ito K; Aono A; Wada M
    Kekkaku; 2007 Feb; 82(2):95-101. PubMed ID: 17373318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis.
    Becerra MC; Freeman J; Bayona J; Shin SS; Kim JY; Furin JJ; Werner B; Sloutsky A; Timperi R; Wilson ME; Pagano M; Farmer PE
    Int J Tuberc Lung Dis; 2000 Feb; 4(2):108-14. PubMed ID: 10694087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
    Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
    Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapy of tuberculosis].
    Eier A; Grass S
    Wien Med Wochenschr; 1994; 144(8-9):186-8. PubMed ID: 7941607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-tuberculosis chemotherapy].
    Wada M
    Kekkaku; 2007 Oct; 82(10):771-81. PubMed ID: 18018601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis.
    Mitchison DA
    Int J Tuberc Lung Dis; 1998 Jan; 2(1):10-5. PubMed ID: 9562106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitubercular chemotherapy].
    Jouveshomme S; Dautzenberg B
    Rev Mal Respir; 1997 Dec; 14 Suppl 5():S88-104. PubMed ID: 9496594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a 12-month regimen for drug-resistant pulmonary tuberculosis.
    Pérez-Guzmán C; Vargas MH; Martínez-Rossier LA; Torres-Cruz A; Villarreal-Velarde H
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1102-9. PubMed ID: 12546119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mycobacterium tuberculosis resistance to antitubercular agents in Antananarivo in 2000].
    Ratsirahonana O; Rasolofo Razanamparany V; Rasolonavalona T; Rakotonirina V; Rakotoarisaonina A; Rakotoherisoa A; Ralamboson M; Cauchoix B; Rakotondramarina D; Ramarokoto H
    Arch Inst Pasteur Madagascar; 2002; 68(1-2):44-7. PubMed ID: 12643091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
    Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
    East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study of drug resistance in previously treated tuberculosis patients in Gujarat, India.
    Shah AR; Agarwal SK; Shah KV
    Int J Tuberc Lung Dis; 2002 Dec; 6(12):1098-101. PubMed ID: 12546118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Disseminated tuberculosis with a multiresistant strain of Mycobacterium tuberculosis in an HIV-infected Swiss male].
    Günthard H; Fuhrer HP; Pfyffer GE; Ruef C; Lüthy R
    Schweiz Rundsch Med Prax; 1993 Oct; 82(40):1108-11. PubMed ID: 8210881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.